Common Stock, par value $0.001
- Symbol
- BIXT
- Exchange
- OTC
- Classification
- COMMON
- Status
- Current
Current Report · Items 8.01, 9.01 · 8-K
Bioxytran, Inc.
BIXTOTCEQUITYCurrent
Other Events
Item 8.01. Other Events On March 2, 2026, the Company issued a press-release over Globe Newswire, enclosed hereto as Exhibit 99.1, under the title: Bioxytran, Inc. Reports Positive Phase 1b/2a Clinical Study Results for ProLectin-M, a Broad-Range Antiviral Drug in Mild to Moderate COVID-19
Company context
Bioxytran, Inc. (“we”, “us”, or the “Company”) is a clinical stage pharmaceutical company focused on the development, manufacture and commercialization of therapeutic drugs designed to address hypoxia (a lack of oxygen to tissues) in humans. Hypoxia needs to be addressed quickly, otherwise it results in necrosis, the death of cells comprising body tissue. Necrosis cannot be reversed. Our lead drug candidate, a hypoxia platform technology with code-name BXT-25, is planned to be an Acellular Oxygen Carrier (“AOC”) consisting of bovine hemoglobin stabilized with a co-polymer. BXT-25’s intended application includes the treatment of hypoxic conditions in the brain resulting from stroke. We believe that our approach is novel when applied to hypoxic conditions in humans. Our drug development efforts are guided by specialists who work on co-polymer chemistry and other disciplines. We intend to supplement our efforts with input from a scientific and medical advisory board whose members include leading physicians.
Current securities
Registered securities in this filing
BIOXYTRAN, INC. · 8-K · Filed 2026-03-02
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item
8.01. Other Events
On
March 2, 2026, the Company issued a press-release over Globe Newswire, enclosed hereto as Exhibit 99.1, under the title:
Bioxytran,
Inc. Reports Positive Phase 1b/2a Clinical Study Results for ProLectin-M, a Broad-Range Antiviral Drug in Mild to Moderate COVID-19
Filed exhibits (1)
EX-99.1 2 ex99-1.htm EX-99.1 EXHIBIT 99.1 Bioxytran, Inc. Reports Positive Phase 1b/2a Clinical Study Results for ProLectin-M, a Broad-Range Antiviral Drug in Mild to Moderate COVID-19 Randomized, Double-Blind, Placebo-Controlled Study Demonstrates 90% Day-5 Viral Clearance and Favorable Safety at Highest Dose compared to 20% placebo control BOSTON, MA - Bioxytran, Inc. (OTCQB: BIXT), a clinical-stage biotechnology company developing carbohydrate-based therapeutics, today announced results from a randomized, double-blind, placebo-controlled Phase 1b/2a clinical study evaluating oral ProLectin-M in hospitalized patients with mild to moderate COVID-19 caused by SARS-CoV-2. The study showed that the highest evaluated dose of ProLectin-M (16,800 mg/day) was associated with statistically significant earlier viral clearance and faster clinical improvement by Day 5 compared with placebo, while demonstrating a favorable safety and tolerability profile. By Day 7, viral clearance was observed across all study arms, consistent with the expected natural resolution of infection in this population, indicating the treatment effect may be related to accelerating viral clearance. No serious…
Open exhibit ↗